PLXDC2 and neoplasm: Peptide‐mediated inhibition of the PLXDC2‐cortactin binding led to a reduction in the mRNA levels of the tumor‐related genes MYC (p < 0.05) and POU5C1, and the proliferation‐related gene MKI67 (p < 0.05) (Figure 5E), while the mRNA levels of PLXDC2 and cortactin remained unchanged (Figure 5E).